OPKO Health announced topline results from phase 2 trial evaluating RAYALDEE to treat symptomatic COVID-19 outpatients

,

On Dec. 23, 2021, OPKO announced preliminary topline results from its Phase 2 trial with RAYALDEEﾮ to treat mild-to-moderate COVID-19.

This study built on increasing medical evidence that vitamin D repletion therapy can mitigate the severity of upper respiratory tract infections and accelerate recovery from COVID-19.

Tags:

,

Source: OPKO Health
Credit:

Visit News/History Source
Transfection Has Never Been So Easy With Avalanche® Transfection Reagents for Cancer Cells, Primary Cells, And Other Difficult-To-Transfect Cells.Primary Cells, And Other Difficult-To-Transfect Cells.